Commercial COVID-19 serial seroconversion panel for validation of SARS-CoV-2 antibody assays-Reference-Cited by-同舟云学术

Commercial COVID-19 serial seroconversion panel for validation of SARS-CoV-2 antibody assays

Published:2020-09-20 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Belda Francisco,Cherenzia Robin,Crowley Michael

Abstract

AbstractBackgroundSeroconversion panels (SCP) are an important tool for investigating antibody responses and developing serological assays. A SCP was generated from a single SARS-CoV-2 positive plasma donor over 87 days.MethodsThis SCP was tested against five SARS-CoV-2 antibody tests (IgG, IgM and total Ig). All test kits utilized recombinant antigens that are specific to SARS-CoV-2.ResultsThe SCP showed IgG responses for SARS-CoV-2 after day 50. IgM levels peaked on day 50 (prior to IgG) and declined in subsequent samples.ConclusionThis SCP is a useful tool for validation of SARS-CoV-2 antibody assays.

Publisher

Cold Spring Harbor Laboratory

Reference12 articles.

1. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

2. Center for Systems Science and Engineering at Johns Hopkins University. COVID-19 Dashboard. Available at: https://coronavirus.jhu.edu/map.html Accessed 6 July 2020.

3. A pneumonia outbreak associated with a new coronavirus of probable bat origin

4. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health. FDA Guidance, Class II Special Controls Guidance Document: Hepatitis A Virus Serological Assays (February 2006). Available at: https://www.fda.gov/media/71388/download. Accessed July 6 2020.

5. Procleix SARS-CoV-2 Assay package insert, GDSS-IFU-000049. https://www.diagnostic.grifols.com/documents/28901102/1023822825/Procleix+SARS-CoV-2+IFU_GDSS-IFU-000049/ed6b34af-a8f3-4011-b15c-9f0222a86136. Accessed July 31, 2020.